Overview

Inuniv and Working Memory

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

Minimum 24 subjects aged 8-12 with a diagnosis of ADHD will be prescribed extended release guanfacine (Intuniv) to assess impact, if any, on working memory. Pre and post testing using a standardized battery of tests for effect on symptoms of ADHD and working memory will be administered and assessed.

Phase:

Phase 4

Details

Lead Sponsor:

Lori A. Schweickert, MD

Collaborator:

Shire

Treatments:

Guanfacine